Hierfür ist eine Anmeldung erforderlich. Bitte registrieren Sie sich bei uns oder melden Sie sich mit Ihren Zugangsdaten an.
DefinitionThis section has been translated automatically.
Polyetiologic, chronic inflammatory disease of variable etiology that may be associated with superficial or deep sclerosis of the dermis and/or subcutis, as well as internal organs.
The disease symptoms may show clinical-morphological signs of circumscritic scleroderma or systemic scleroderma, thus mimicking them. The most common case of pseudoscleroderma is indurations in chronic venous insufficiency, CVI .
ClassificationThis section has been translated automatically.
According to etiology, one distinguishes:
- Infectious causes:
- Drug- or toxin-induced:
- Toxic oil syndrome
- Eosinophilic myalgia syndrome (L-tryptophan)
- Epoxy resins
- Pseudoscleroderma due to drugs: phenobarbital, D-penicillamine, gold preparations, hepatitis B vaccine, captopril, spironolactone, allopurinol, bleomycin, doxetaxel, cisplatin, pentazocine, (centrally acting analgesic), cocaine, appetite suppressants
- Metabolic-induced:
- Foreign material-induced:
- Silicone or kerosene implants(?)
- Polyvinyl chloride disease
- Nephrogenic systemic fibrosis.
- Congestive syndromes:
- Idiopathic- or immunologic-induced:
- Progeria adultorum (Werner syndrome)
- Progeria infantilis
- Fasciitis, eosinophilic
- Sclerofascia
- Fibrosis, oral submucosal
- Graft-versus-host disease, chronic
- Fibrosis, nephrogenic systemic (Nephrogenic fibrosing dermopathy)
- Stiff-skin syndrome
- Paraneoplastic-induced:
- Bronchial carcinoma
- Metastatic carcinoid
- Immunocytic lymphoma.
- Physically induced:
- Psychogenically induced:
- See below Psychosomatics.
TherapyThis section has been translated automatically.
Treatment of the underlying disease.
LiteratureThis section has been translated automatically.
- Barth J, Kleemann W (1972) Pseudoscleroderma in silicosis. Z Skin Sexkr 47: 123-134
- Behrens S et al (1998) Bleomycin-induced PSS-like pseudoscleroderma. Case report and review of the literature. dermatologist 49: 725-729
- Bretza J, Goldman JA (1979) Scleroderma simulating vinyl chloride disease. J Occup Med 21: 436-438
- Fabris M, Hunzelmann N (2007) Differential diagnosis of scleroderma and psuedoscleroderma. JDDG11:977-984
- Fujii T et al (2003) Pseudoscleroderma associated with transforming growth factor beta1-producing advanced gastric carcinoma: comment on the article by Varga. Arthritis Rheum 48: 1766-1767
- Gray RG, Gottlieb NL (1981) Pseudoscleroderma in hypertrophic osteoarthropathy. JAMA 246: 2062-2063
- Guillet GY et al (1983) Pseudoscleroderma and phenylketonuria. Int J Dermatol 22: 422-426
- Haustein UF (1992) Chemically induced scleroderma. dermatologist 43: 469-474
- Jablonska S (1967) Pseudoscleroderma. Med Small 62: 1151-1154
- Jung AG et al (2010) Unusual chronic scleroderma graft-versus-host disease. dermatologist 61: 514-517
- Pang BK et al (1996) Pseudoscleroderma secondary to phytomenadione (vitamin K1) injections: Texier's disease. Australas J Dermatol 37: 44-47
- Querfeld C et al (2000) Pseudoscleroderma associated with lung cancer: correlation of collagen type I and connective tissue growth factor gene expression. Br J Dermatol 142: 1228-1233
- Roses RM (1992) Localized scleroderma and Borrelia antibody seroconversion. Int J Dermatol 31: 820
- Takagawa S et al (2003) Sustained activation of fibroblast transforming growth factor-beta/Smad signaling in a murine model of scleroderma. J Invest Dermatol 121: 41-50
- Yamamoto T, Nishioka K (2002) Analysis of the effect of halofuginone on bleomycin-induced scleroderma. Rheumatology (Oxford) 41: 594-596
- Yamamoto T et al (2001) Mast cell-independent increase of type I collagen expression in experimental scleroderma induced by bleomycin. Arch Dermatol Res 293: 532-536
- Yamamoto T, Nishioka K (2002) Animal model of sclerotic skin. V: Increased expression of alpha-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. Clin Immunol 102: 77-83
- Yamamoto T, Nishioka K (2003) Role of monocyte chemoattractant protein-1 and its receptor, CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 121: 510-516
- Yamamoto T et al (2002) Analysis of the effect of halofuginone on bleomycin-induced scleroderma. Rheumatology (Oxford) 41: 594-596
Incoming links (7)
Bleomycin; Cocaine; Graft-versus-host disease; Polyvinyl chloride disease; Porphyria cutanea tarda; Toxic oil syndrome; Toxic oil syndrome;Outgoing links (32)
Amyloidosis (overview); Bleomycin; Carcinoid syndrome; Chronic venous insufficiency (overview); Circumscribed scleroderma; Cisplatin; Cocaine; Dermatoliposclerosis; Diabetes mellitus skin changes; Eosinophilic myalgie syndrome; ... Show allDisclaimer
Please ask your physician for a reliable diagnosis. This website is only meant as a reference.